Susquehanna International Group, LLP Halozyme Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

A detailed history of Susquehanna International Group, LLP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 38,259 shares of HALO stock, worth $2.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,259

Previous 60,833 37.11%

Holding current value

$2.17 Million

Previous $2.47 Million 19.04%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$37.81 - $52.4 $853,522 - $1.18 Million	-22,574 Reduced 37.11%	38,259 $2 Million
Q1 2024 May 07, 2024	SELL	$33.68 - $41.95 $679,729 - $846,634	-20,182 Reduced 24.91%	60,833 $2.47 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $961,981 - $1.22 Million	-28,871 Reduced 26.27%	81,015 $2.99 Million
Q3 2023 Nov 14, 2023	SELL	$36.46 - $44.03 $274,325 - $331,281	-7,524 Reduced 6.41%	109,886 $4.2 Million
Q2 2023 Aug 11, 2023	SELL	$30.28 - $38.74 $1.38 Million - $1.76 Million	-45,416 Reduced 27.89%	117,410 $4.23 Million
Q1 2023 May 16, 2023	BUY	$32.86 - $55.7 $2.28 Million - $3.86 Million	69,368 Added 74.22%	162,826 $6.22 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $3.3 Million - $4.89 Million	-82,285 Reduced 46.82%	93,458 $5.32 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $3.06 Million - $4.11 Million	79,412 Added 82.44%	175,743 $6.95 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $1.64 Million - $2.12 Million	43,841 Added 83.52%	96,331 $4.24 Million
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $2.75 Million - $3.54 Million	-86,138 Reduced 62.14%	52,490 $2.09 Million
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $1.91 Million - $2.45 Million	60,097 Added 76.53%	138,628 $5.58 Million
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $2.16 Million - $2.6 Million	56,087 Added 249.9%	78,531 $3.19 Million
Q2 2021 Aug 11, 2021	SELL	$38.84 - $51.31 $823,252 - $1.09 Million	-21,196 Reduced 48.57%	22,444 $1.02 Million
Q1 2021 May 17, 2021	BUY	$39.51 - $51.45 $639,034 - $832,152	16,174 Added 58.89%	43,640 $1.82 Million
Q4 2020 Feb 16, 2021	SELL	$25.81 - $43.62 $314,985 - $532,338	-12,204 Reduced 30.76%	27,466 $1.17 Million
Q3 2020 Nov 16, 2020	SELL	$25.74 - $29.63 $1.74 Million - $2 Million	-67,418 Reduced 62.96%	39,670 $1.04 Million
Q2 2020 Aug 14, 2020	BUY	$16.25 - $26.81 $689,357 - $1.14 Million	42,422 Added 65.6%	107,088 $2.87 Million
Q1 2020 May 15, 2020	SELL	$13.9 - $21.83 $498,898 - $783,522	-35,892 Reduced 35.69%	64,666 $1.16 Million
Q4 2019 Feb 14, 2020	BUY	$14.93 - $19.53 $47,328 - $61,910	3,170 Added 3.26%	100,558 $1.78 Million
Q3 2019 Nov 14, 2019	SELL	$15.2 - $17.69 $1.28 Million - $1.49 Million	-84,026 Reduced 46.32%	97,388 $1.51 Million
Q2 2019 Aug 16, 2019	BUY	$14.75 - $17.26 $771,307 - $902,559	52,292 Added 40.5%	181,414 $3.12 Million
Q2 2019 Aug 14, 2019	SELL	$14.75 - $17.26 $507,473 - $593,830	-34,405 Reduced 21.04%	129,122 $2.22 Million
Q4 2018 Feb 14, 2019	BUY	$13.33 - $18.66 $885,591 - $1.24 Million	66,436 Added 68.43%	163,527 $2.39 Million
Q3 2018 Nov 14, 2018	SELL	$16.68 - $18.41 $3.1 Million - $3.42 Million	-185,652 Reduced 65.66%	97,091 $1.76 Million
Q2 2018 Aug 14, 2018	BUY	$16.87 - $20.3 $1.23 Million - $1.48 Million	73,091 Added 34.86%	282,743 $4.77 Million
Q1 2018 May 15, 2018	SELL	$17.06 - $21.2 $1.43 Million - $1.78 Million	-84,039 Reduced 28.61%	209,652 $4.11 Million
Q4 2017 Feb 14, 2018	BUY	$16.75 - $20.8 $4.92 Million - $6.11 Million	293,691	293,691 $5.95 Million

Others Institutions Holding HALO

# of Institutions

488

Shares Held

122M

Call Options Held

208K

Put Options Held

66.3K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.89B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Halozyme Therapeutics, Inc. Transaction History